Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Poolbeg Pharma Ltd. ( (GB:POLB) ) just unveiled an announcement.
Poolbeg Pharma has secured its first national patent grant for cancer immunotherapy-induced Cytokine Release Syndrome from IP Australia, covering the use of any p38 MAPK inhibitor, including lead asset POLB 001, to prevent this serious side effect. The protection, supported by proprietary company data and advanced through expedited international patent pathways, marks a significant milestone in building Poolbeg’s global IP estate for both oncology and severe influenza.
Management said the Australian patent strengthens POLB 001’s future value and attractiveness to partners as the TOPICAL trial in multiple myeloma patients moves toward interim data in summer 2026. The company expects this initial grant to support further jurisdictional coverage, reinforcing its strategy to expand safer cancer immunotherapies beyond specialist centres and enhance its competitive positioning in high-value therapeutic markets.
The most recent analyst rating on (GB:POLB) stock is a Hold with a £4.50 price target. To see the full list of analyst forecasts on Poolbeg Pharma Ltd. stock, see the GB:POLB Stock Forecast page.
Spark’s Take on POLB Stock
According to Spark, TipRanks’ AI Analyst, POLB is a Neutral.
The score is primarily held back by weak financial performance (no revenue, widening losses, and ongoing cash burn with declining equity), partially offset by a debt-free balance sheet. Technicals are moderately supportive with price above key longer-term moving averages and neutral momentum. Valuation remains unattractive/unclear because the company is loss-making and offers no dividend yield.
To see Spark’s full report on POLB stock, click here.
More about Poolbeg Pharma Ltd.
Poolbeg Pharma plc is a clinical-stage biopharmaceutical company focused on transforming the cancer immunotherapy field. Its lead asset, POLB 001, aims to prevent life-threatening Cytokine Release Syndrome to make immunotherapies safer and more widely usable, while the company also develops an oral GLP-1 obesity therapy targeting a major global market.
Average Trading Volume: 1,271,832
Technical Sentiment Signal: Hold
Current Market Cap: £29.61M
For an in-depth examination of POLB stock, go to TipRanks’ Overview page.